Sun Pharma:
₹1,54,691 Cr Revenue. 31.9% EBITDA Margin.
The Innovation Bet Is Finally Hitting.
Highest-ever quarterly revenue. EBITDA margin at a five-year peak. And for once, the growth is not coming from lucky milestones or one-time settlements—it’s coming from the products the company actually built.
The Pharma Giant That Looks Expensive But Is Actually Earning It
- Q3 FY26 Revenue₹1,54,691 Cr
- Q3 FY26 PAT₹33,688 Cr
- Q3 FY26 EPS₹14.04
- Annualised EPS (Q3×4)₹56.16
- 9M FY26 Revenue₹4,36,604 Cr
- Book Value (Sep 2025)₹324
- Price to Book5.55x
- P/E vs Industry35.6x vs 27.7x
- Net Debt / EBITDANegative (Net Cash)
- 3-Year CAGR Profit20.2%
The Comeback Kid. Again.
Sun Pharmaceutical is India’s largest pharma company by revenue. If you’ve taken a pill made by an Indian pharma firm—and statistically, you have—there’s a decent chance it was a Sun Pharma pill. They sell generics in America, branded pills in India, and increasingly, specialty products globally. They’ve built 41 manufacturing facilities across six continents, filed 650 ANDA approvals in the US, and somehow still find time to make shareholders nervous every six months with their latest regulatory complaint or facility inspection.
But here’s the plot twist: the company that spent five years being meme’d for its regulatory troubles is now finally extracting value from the innovation pipeline it built. UNLOXCYT—their cutaneous squamous cell carcinoma drug—launched in the US. LEQSELVI—their hair regrowth JAK inhibitor—got approval in the US and early feedback says it’s working. India sales are growing at 3x the market rate. And net debt is negative, meaning they’re sitting on ₹3.2 billion in net cash.
The stock trades at 35.6x P/E. In isolation, that’s eye-watering. But when you’re a 20.2% profit CAGR company with a diversified global footprint, 20.2% ROCE, and a pipeline that’s finally printing results, maybe—just maybe—the market is pricing in something real.
₹4.3 Trillion Market Cap. Five Revenue Streams. Zero Excitement.
Sun Pharma is a five-legged beast.
India Formulations (32% of revenue, 9M FY26): Sun is #1 in the Indian pharmaceutical market with 8.4% market share—ahead of every competitor. They sell branded pills for neuropsychiatry (20% of segment), cardiology (17%), and gastroenterology (14%). Volume growth in 9M FY26 was 6.3% vs IPM volume growth of 1.2%. Meaning they’re stealing share from competitors even while the market grows slowly. In Feb 2026, management flagged two approvals for semaglutide—both for T2D and obesity—positioning them for a day-one generic launch post patent expiry.
US Generics (29% of revenue, 9M FY26): Sun is the 12th-largest generics player in the US. But generics are a race to the bottom. Pricing pressure is relentless. Q3 saw 0.6% YoY growth—basically flat—because while innovation products grew, generic volumes got hammered by “additional competition in certain products.” Management admits the constrained supply at facilities like Halol and Mohali is limiting new product launches. They’re building a new facility in Madhya Pradesh to fix this, but it’s a 2-3 year play.
Emerging Markets (25% of 9M FY26): Romania, Brazil, South Africa, Mexico. Growing at 21.6% YoY. Low double-digit growth constant currency. Distribution-led play with 2,500+ sales reps.
Innovation / Specialty (20% of global sales): This is where the excitement lives. Ilumya (psoriasis), LEQSELVI (hair loss), UNLOXCYT (cancer), Cequa (dry eye). These grew at 14.3% YoY in Q3, excluding milestones. Management is plowing cash into launches—explicitly calling out LEQSELVI and UNLOXCYT investment that will “become part of core OPEX next year.”
APIs & Consumer Health: Smaller, profitable. Consumer health is top 5 in India. Nutritional and wellness play.
Q3 FY26: The Numbers
Result type: Quarterly Results | Q3 FY26 EPS: ₹14.04 | Annualised EPS (Q3×4): ₹56.16 | 9M FY26 EPS (prorated): ₹36.51 (9M / 9 × 12)
Source table
| Metric (₹ Mn) | Q3 FY26 Dec 2025 |
Q3 FY25 Dec 2024 |
Q2 FY26 Sep 2025 |
YoY % | QoQ % |
|---|---|---|---|---|---|
| Revenue | 154,691 | 134,372 | 144,780 | +15.1% | +6.8% |
| Operating Profit | 49,485 | 40,072 | 44,527 | +23.4% | +11.1% |
| EBITDA Margin % | 31.9% | 29.8% | 30.7% | +210 bps | +120 bps |
| PAT | 33,688 | 29,079 | 31,250 | +15.8% | +7.8% |
| EPS (₹) | 14.04 | 12.10 | 13.00 | +15.9% | +8.0% |
Is 35.6x P/E For A Pharma Company Insane?
Method 1: P/E Based
FY26 annualised EPS = ~₹47–50 (conservative). Industry median P/E = 27.7x. Sun’s justified premium for innovation pipeline + global diversification + ROCE leadership: 1.2x–1.5x sector. Fair P/E band: 30x–40x.
Range: ₹1,410 – ₹2,000
Method 2: EV/EBITDA Based
FY26 EBITDA (annualised) = ~₹1,85,000–1,90,000 million. Current Enterprise Value = ₹4,25,081 Cr. Current EV/EBITDA = 22.4x (approx). Pharma comps: 18x–26x. Sun at lower-mid range due to regulatory overhang and execution risk.
EV range (19x–24x): ₹3,51,500–4,56,000 Cr → Per share (net of cash):
Range: ₹1,380 – ₹1,820
Method 3: DCF Based
Base FCF (9M FY26 operating CF): ~₹95,000+ million annually. Growth: 10–12% for 5 years (conservative vs 20% profit CAGR). Terminal growth: 3%. WACC: 9.5% (given net cash position).
→ Terminal Value (3% growth / 6.5% cap rate): ~₹3,75,000 Cr
→ Total EV: ~₹9,25,000 Cr (includes net cash of ~$3.2bn = ~₹27,000 Cr)
Range: ₹1,500 – ₹2,150
The Plot Thickens. Again.
🟢 The Wins: UNLOXCYT & LEQSELVI Launch, Semaglutide Approved
UNLOXCYT (aCSCC drug) launched in the US in January 2026. Early commentary: health system access discussions “progressing positively” with top 50 cancer centers. LEQSELVI (alopecia areata) got FDA approval; early physician feedback shows hair regrowth “mirrors clinical data.” Both are investment-mode launches (incremental spend on HCP education, patient access programs), but launches are happening. Semaglutide approvals for India (both indications) are done. Noveltreat and Sematrinity are ready for market. This isn’t theoretical. This is execution happening in real-time.
⚠️ The Lingering Problems
- • Halol facility: OAI classification (Sept 2025)
- • Baska facility: OAI classification (Dec 2025)
- • Mohali, Dadra: Still subject to consent decree provisions
- • Import alerts restrict US shipments until compliance restored
- • Regulatory non-compliance is limiting US generics launches
✅ The Workarounds
- • New greenfield facility approved in Madhya Pradesh (₹3,000 Cr capex)
- • NCLT approved five-subsidiary amalgamation (Nov 2025)
- • $200 million antitrust settlement closed (Jul 2025)
- • Net cash position: US$3.2 billion (no debt stress)
- • Checkpoint Therapeutics acquisition (immunotherapy) for $355 Mn
Fortress or Farce?
Source table
| Item (₹ Cr) | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 (Latest) |
|---|---|---|---|---|
| Total Assets | 80,712 | 85,328 | 91,908 | 1,03,706 |
| Total Equity (Reserves) | 55,995 | 63,667 | 72,218 | 77,820 |
| Borrowings | 6,886 | 3,274 | 2,362 | 5,215 |
| Other Liabilities | 17,831 | 18,387 | 17,328 | 20,672 |
| Total Liabilities | 80,712 | 85,328 | 91,908 | 1,03,706 |
Debt: ₹5,215 Cr. Cash & Investments: ~₹32,500 Cr (as of Dec 2025 net cash US$3.2bn). Net debt is negative. Zero debt stress. Can drop ₹3,000 Cr on Madhya Pradesh facility without blinking.
Reserves grew from ₹55,995 Cr (Mar 2023) to ₹77,820 Cr (Sep 2025). Retained earnings are funding growth. No secondary dilution needed.
Days Payable 210 days. Debtor Days 91 days. Inventory Days 348 days. Cash cycle is neutral-to-positive. Not a liquidity issue.
Operating CF: The Unsung Hero
Source table
| Cash Flow (₹ Cr) | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Operating CF | +4,959 | +12,135 | +14,072 |
| Investing CF | -7,220 | -763 | -5,183 |
| Financing CF | +2,376 | -6,710 | -7,906 |
| Net Cash Flow | +115 | +4,662 | +983 |
Is This Expensive? Or Just Expensive-But-Justified?
Four-Year Revenue & Profit Trajectory
Source table
| Metric (₹ Cr) | FY2023 | FY2024 | FY2025 | TTM (12M) |
|---|---|---|---|---|
| Revenue | 43,886 | 48,497 | 52,578 | 56,809 |
| Operating Profit | 11,650 | 13,018 | 15,114 | 17,493 |
| OPM % | 27% | 27% | 29% | 31% |
| PAT | 8,513 | 9,610 | 10,965 | 10,953 |
| EPS (₹) | 35.32 | 39.91 | 45.55 | 45.50 |
Revenue is growing mid-single digits. But EPS is growing 13%+ because (1) operating leverage (OPM expanding 400 bps), and (2) better product mix (specialty/innovation mix > generic mix). This is not a growth story. This is a margin expansion story wrapped inside a growth story.
Sun vs. The Pharma Class (And Why It Stands Apart)
Source table
| Company | Sales (₹ Cr) | PAT (₹ Cr) | OPM % | P/E | ROCE % |
|---|---|---|---|---|---|
| Sun Pharma | 56,809 | 10,953 | 31% | 35.6x | 20.2% |
| Divi’s Lab | 10,314 | 2,533 | 33% | 66.3x | 20.4% |
| Torrent Pharma | 12,742 | 2,306 | 33% | 63.4x | 27.1% |
| Dr Reddy’s Labs | 34,682 | 5,568 | 23% | 19.6x | 22.7% |
| Lupin | 26,151 | 4,974 | 29% | 21.5x | 21.3% |
Divi’s Lab and Torrent trade at 63x–66x P/E. They’re smaller, higher-margin, lower-risk. Sun at 35.6x is a bargain by comparison. But it’s also the only one with meaningful regulatory overhang. The “valuation discount” reflects the risk premium investors demand for compliance uncertainty.
Who Runs This Show?
- Promoters (Shanghvi family)54.48%
- Public8.57%
- DIIs (incl. LIC 4.93%)20.72%
- FIIs16.12%
Pledge: 0.97%. Stable shareholding for a decade. No major dilution or share buyback activity. Promoters are very much in control.
Promoter: Shanghvi Family
Dilip Shanghvi (founder, 9.60%) and family entities control via Shanghvi Finance Private Limited (40.30%). Silent, steady, long-term focused. Dilip has been explicit: Sun is a “50-year company.” Not a flipper’s game.
LIC Holds 4.93% 👀
Insurance money is now a significant holder. Likely via structured fund mandates. Signals institutional comfort with the company despite regulatory noise.
Angels or Devils?
✅ The Positives
- ✓ ICRA reaffirmed ratings (March 2025) — AAA/A1+ on long-term debt
- ✓ Clean audit history (no material qualifications in recent years)
- ✓ Consistent dividend policy (33.8% payout maintained)
- ✓ R&D spending at 5.8% of sales (higher than peer average)
- ✓ 41 manufacturing facilities, 3,000 R&D professionals globally
- ✓ Pledge: 0.97% (promoter committed)
⚠️ The Thorns in the Side
- ⚠ Halol facility: OAI (Observation of Advisory Item) since Sep 2025
- ⚠ Baska facility: OAI classification since Dec 2025
- ⚠ Mohali, Dadra: Ongoing consent decree oversight
- ⚠ Litigation: Multiple product liability + patent + antitrust cases
- ⚠ $200 Mn antitrust settlement (Jul 2025) — price fixing allegations
- ⚠ Import Alerts limit US shipments until compliance restored
The Indian Pharma Paradox: Global Player, Domestic Headwinds
India’s pharmaceutical industry is the world’s “pharmacy”—making generics for everyone. But it’s a race to the bottom. Price erosion is relentless. Regulatory changes in the US (CMS “Most Favored Nation” pricing, biosimilar competition, supply chain reshoring) are structural headwinds. Yet India continues to grow, because:
🏥 India’s Chronic Disease Boom
Diabetes, hypertension, neuropsychiatry—India’s disease burden is growing. 1.4 billion people means 100+ million diabetics by conservative estimates. Chronic market growing 10–12% annually. Sun’s 6.3% volume growth in India is outpacing this because they’re winning share via better distribution, better brands, and better access. This is not speculation—it’s mathematics.
🧬 The Innovation Shift (Specialty > Generics)
Global pharma is shifting from commodity generics to specialty/innovative products. Higher margins, less competition, longer exclusivity. Sun sees this. UNLOXCYT, LEQSELVI, GL0034—all specialty plays. Management explicitly said innovation is “part of long-term strategy.” This is the future of the company.
⚖️ US Generics Regulation as a Moat
FDA compliance is expensive. Most Indian competitors can’t afford it. Halol and Baska aren’t accidents—they’re the cost of scale in regulated markets. Sun’s manufacturing footprint (41 facilities) is overkill for a smaller company but essential for a global player. Regulatory overhang is temporary. The moat is permanent.
📉 US Generics Price Erosion
US generics pricing down 5–8% YoY industry-wide. Sun’s US generics revenue growth was +0.6% in Q3—basically flat. This is not going away. The solution: innovation mix + emerging markets + India branded. Sun is executing all three, but it’s a slow pivot.
Macro context: INR strength is a tailwind for pharma (imports cheaper, exports more valuable in INR terms). US healthcare spending remains robust. Emerging markets (Brazil, Mexico, Romania) are growing 15–20% annually in local currency. Data centre cooling (UK R&D on immersion fluids) is a multi-year optionality. Nothing earth-shaking, but all incrementally positive.
The Pill That Tastes Expensive
Sun Pharmaceutical is the pharma industry’s version of a levering play that actually delivered leverage. For a decade, the narrative was “regulatory overhang + generic pricing pressure = slow death.” But instead, the company built an innovation pipeline, captured 3x market growth in India, and is now printing 31.9% EBITDA margins at 15% revenue growth.
Q3 FY26 Execution: ₹1,54,691 crore revenue (highest ever). 31.9% EBITDA margin (five-year peak). Innovation segment growing 14.3% ex-milestones. India volume growth at 6.3% vs IPM 1.2%. The operational leverage is real. The product launches are real. The macro tailwinds are real.
The Valuation Case: At ₹1,799, Sun trades at 35.6x P/E. By absolute standards, that’s pricey. But by relative standards—a company growing profit 20%+ annually, carrying net cash, expanding EBITDA margins, and diversified across four geographies—it’s justified. Fair value range of ₹1,380–₹2,150 brackets the current price in the upper-middle. Not cheap. Not expensive. Fair-to-slightly-premium.
The Regulatory Wildcard: Halol, Baska, Mohali, Dadra—all under FDA scrutiny. Import Alerts limit US shipments. Madhya Pradesh facility is being built (₹3,000 crore) to address this, but it’s a 2–3 year play. This is not going away soon. The rating agencies say “stable outlook,” but that’s conditional on no further deterioration. One more major finding could reprobe the narrative.
Historical Context: Over the past 5 years, Sun stock price CAGR: 24%. A multiple expansion story (P/E re-rating from ~25x to 35x) helped, but underlying profit growth (24% CAGR over 5 years) was the engine. The question is: can the company extend this into the next five years? The answer depends on three things: (1) innovation pipeline delivery, (2) India volume momentum, (3) regulatory compliance restoration.
✓ Strengths
- Largest pharma company in India (8.4% IPM share)
- Profit CAGR 20%+ (3 years); 24% (5 years)
- EBITDA margin expanding (27% → 31% in 3 years)
- Innovation portfolio growing 14.3% ex-milestones
- India volume growth 6.3% vs IPM 1.2% (share capture)
- Net cash position (US$3.2 billion)
- Emerging markets growing 21.6% YoY
✗ Weaknesses
- Revenue growth capped at 10–12% (mature markets)
- US generics segment flat/declining due to competition
- Regulatory non-compliance at 4 key facilities
- Import Alerts limiting US shipments
- Dividend payout high (33.8%) — limits capex flexibility
- R&D-heavy model (5.8% of sales) = persistent cost
→ Opportunities
- Semaglutide (GLP-1) day-one generic launch in India
- UNLOXCYT & LEQSELVI commercial ramp (US, global)
- Emerging markets (Brazil, Mexico, Romania) scaling
- Data centre immersion cooling fluids (pilot stage)
- Specialty portfolio expansion (pipeline robust)
- Madhya Pradesh facility coming online (2–3 years)
⚡ Threats
- US FDA regulatory findings could worsen
- Further manufacturing facility compliance issues
- US generics market continues pricing erosion
- Patent expirations on key products (Ilumya, etc.)
- Emerging market competition intensifying
- INR appreciation headwind on USD revenues
Sun Pharmaceutical has stopped being a regulatory-complaint factory and started being a pharmaceutical company again.
The innovation portfolio is real. The India growth is real. The margin expansion is real. The regulatory issues are also real—but they’re being addressed, not ignored. At ₹1,799, the stock is fairly valued for a company executing at this level, not undervalued for a company about to explode. If the company can restore manufacturing compliance within 12–18 months while maintaining innovation momentum, the stock could easily hit ₹2,000+. If regulatory issues deepen, it could contract toward ₹1,400. The range is wide because execution visibility is limited.
But for investors comfortable with pharmaceutical upside optionality and willing to tolerate near-term regulatory noise, this is not a bad entry.